These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24187825)

  • 1. [Application of methyl in drug design].
    Lian J; Wang J; Sun HF; Lin DZ; Liu H
    Yao Xue Xue Bao; 2013 Aug; 48(8):1195-208. PubMed ID: 24187825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methyl-containing pharmaceuticals: Methylation in drug design.
    Sun S; Fu J
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3283-3289. PubMed ID: 30243589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lead compound optimization strategy (1)--changing metabolic pathways and optimizing metabolism stability].
    Wang J; Liu H
    Yao Xue Xue Bao; 2013 Oct; 48(10):1521-31. PubMed ID: 24417078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The methylation effect in medicinal chemistry.
    Barreiro EJ; Kümmerle AE; Fraga CA
    Chem Rev; 2011 Sep; 111(9):5215-46. PubMed ID: 21631125
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in aqueous solubility achieved via small molecular changes.
    Walker MA
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5100-5108. PubMed ID: 29100802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational drug design paradigms: the odyssey for designing better drugs.
    Kellici T; Ntountaniotis D; Vrontaki E; Liapakis G; Moutevelis-Minakakis P; Kokotos G; Hadjikakou S; Tzakos AG; Afantitis A; Melagraki G; Bryant S; Langer T; Di Marzo V; Mavromoustakos T
    Comb Chem High Throughput Screen; 2015; 18(3):238-56. PubMed ID: 25747445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biocatalysis: synthesis of chiral intermediates for drugs.
    Patel RN
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):741-64. PubMed ID: 17117684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space.
    Vallianatou T; Giaginis C; Tsantili-Kakoulidou A
    Adv Exp Med Biol; 2015; 822():187-94. PubMed ID: 25416989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure.
    Leach AG; Jones HD; Cosgrove DA; Kenny PW; Ruston L; MacFaul P; Wood JM; Colclough N; Law B
    J Med Chem; 2006 Nov; 49(23):6672-82. PubMed ID: 17154498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of pharmaceutical profiling assays for optimization of drug-like properties.
    Di L; Kerns EH
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):495-504. PubMed ID: 16022186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance in Drug Design.
    Smith DA; Beaumont K; Maurer TS; Di L
    J Med Chem; 2019 Mar; 62(5):2245-2255. PubMed ID: 30281973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we rationally design promiscuous drugs?
    Hopkins AL; Mason JS; Overington JP
    Curr Opin Struct Biol; 2006 Feb; 16(1):127-36. PubMed ID: 16442279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective optimization of side activities: another way for drug discovery.
    Wermuth CG
    J Med Chem; 2004 Mar; 47(6):1303-14. PubMed ID: 14998318
    [No Abstract]   [Full Text] [Related]  

  • 16. Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery?
    Smith D; Schmid E; Jones B
    Clin Pharmacokinet; 2002; 41(13):1005-19. PubMed ID: 12403640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive approaches to increase absorption of compounds during lead optimisation.
    Valko K; Butler J; Eddershaw P
    Expert Opin Drug Discov; 2013 Oct; 8(10):1225-38. PubMed ID: 23865945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular determinants of drug-receptor binding kinetics.
    Pan AC; Borhani DW; Dror RO; Shaw DE
    Drug Discov Today; 2013 Jul; 18(13-14):667-73. PubMed ID: 23454741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chirality and drugs in clinical practice and its ethical aspect.
    Banerjee M; Biswas I; Halder S
    J Indian Med Assoc; 2009 Jan; 107(1):41-2. PubMed ID: 19588688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New QSPR study for the prediction of aqueous solubility of drug-like compounds.
    Duchowicz PR; Talevi A; Bruno-Blanch LE; Castro EA
    Bioorg Med Chem; 2008 Sep; 16(17):7944-55. PubMed ID: 18701302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.